Zacks Research Has Negative Outlook for WST Q2 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – Equities researchers at Zacks Research cut their Q2 2027 earnings per share (EPS) estimates for West Pharmaceutical Services in a research note issued to investors on Thursday, March 5th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $2.26 per share for the quarter, down from their previous forecast of $2.27. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q3 2027 earnings at $2.21 EPS.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.21. The firm had revenue of $805.00 million during the quarter, compared to analyst estimates of $795.70 million. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.82 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS.

Other equities analysts also recently issued research reports about the stock. Jefferies Financial Group reissued a “buy” rating and set a $295.00 target price on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Evercore cut their price target on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 3rd. Morgan Stanley initiated coverage on West Pharmaceutical Services in a report on Monday, December 1st. They set an “equal weight” rating and a $285.00 price target for the company. UBS Group reissued a “buy” rating and issued a $340.00 price objective on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, West Pharmaceutical Services has an average rating of “Buy” and a consensus target price of $314.56.

West Pharmaceutical Services Trading Up 0.6%

NYSE:WST opened at $245.92 on Monday. West Pharmaceutical Services has a 52 week low of $187.43 and a 52 week high of $322.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.34 and a current ratio of 3.02. The firm’s fifty day moving average is $253.72 and its 200-day moving average is $262.25. The firm has a market cap of $17.71 billion, a P/E ratio of 36.22, a P/E/G ratio of 2.61 and a beta of 1.17.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Empowered Funds LLC lifted its stake in West Pharmaceutical Services by 16.1% during the 1st quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock valued at $361,000 after acquiring an additional 224 shares in the last quarter. Intech Investment Management LLC boosted its holdings in West Pharmaceutical Services by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after acquiring an additional 1,307 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of West Pharmaceutical Services by 14.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after acquiring an additional 157 shares in the last quarter. Resona Asset Management Co. Ltd. raised its holdings in shares of West Pharmaceutical Services by 16.2% in the second quarter. Resona Asset Management Co. Ltd. now owns 33,559 shares of the medical instruments supplier’s stock valued at $7,344,000 after purchasing an additional 4,676 shares during the last quarter. Finally, Savant Capital LLC purchased a new stake in shares of West Pharmaceutical Services in the second quarter valued at about $400,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services declared that its board has authorized a share repurchase plan on Tuesday, February 17th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 5.6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Stockholders of record on Wednesday, April 29th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Wednesday, April 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.4%. West Pharmaceutical Services’s dividend payout ratio is 12.96%.

West Pharmaceutical Services News Summary

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates for WST (notable changes: FY2026 to $7.85 from $7.52, FY2027 to $8.79 from $8.51, and FY2028 to $10.29) and upgraded multiple quarter forecasts (Q1–Q4 2026 and Q1/Q4 2027). The firm keeps a “Strong‑Buy” rating — a coordinated set of upgrades that tends to support investor conviction and share demand. MarketBeat: West Pharmaceutical Services
• Neutral Sentiment: These revisions largely align with West’s own FY2026 guidance range (7.85–8.20 EPS), so part of the move may reflect confirmation of management direction rather than a surprise beat. Analysts’ models can change and represent expectations, not guarantees.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.